Evidence mapPaperPMID 35269270Full record

ReviewNanomaterials (Basel, Switzerland)2022

Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment.

Mohammad Souri, Mohsen Chiani, Ali Farhangi, Mohammad Reza Mehrabi, Dariush Nourouzian, Kaamran Raahemifar, M Soltani

Open access · goldAbstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Lessons Learned from Liver-on-Chip Platform.Annals of biomedical engineering · 2025
    Review
  4. Article
  5. Review
  6. Metal-based nanoparticle in cancer treatment: lessons learned and challenges.Frontiers in bioengineering and biotechnology · 2024
    Review
  7. Article
  8. Nanomedicine: New Frontiers in Fighting Microbial Infections.Nanomaterials (Basel, Switzerland) · 2023
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Mohammad SouriDepartment of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran.ORCID 0000-0001-9509-1336
Mohsen ChianiDepartment of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran.ORCID 0000-0001-6413-8752
Ali FarhangiDepartment of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran.
Mohammad Reza MehrabiDepartment of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran.
Dariush NourouzianDepartment of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran.
Kaamran RaahemifarData Science and Artificial Intelligence Program, College of Information Sciences and Technology (IST), Penn State University, State College, PA 16801, USA.ORCID 0000-0002-9835-7897
M SoltaniDepartment of Mechanical Engineering, K. N. Toosi University of Technology, Tehran 19967-15433, Iran.ORCID 0000-0003-0878-6274
Pasteur Institute of Iran · IRPennsylvania State University · USUniversity of Waterloo · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the announcement of the outbreak of COVID-19 by the World Health Organization, unprecedented efforts were made by researchers around the world to combat the disease. So far, various methods have been developed to combat this "virus" nano enemy, in close collaboration with the clinical and scientific communities. Nanotechnology based on modifiable engineering materials and useful physicochemical properties has demonstrated several methods in the fight against SARS-CoV-2. Here, based on what has been clarified so far from the life cycle of SARS-CoV-2, through an interdisciplinary perspective based on computational science, engineering, pharmacology, medicine, biology, and virology, the role of nano-tools in the trio of prevention, diagnosis, and treatment is highlighted. The special properties of different nanomaterials have led to their widespread use in the development of personal protective equipment, anti-viral nano-coats, and disinfectants in the fight against SARS-CoV-2 out-body. The development of nano-based vaccines acts as a strong shield in-body. In addition, fast detection with high efficiency of SARS-CoV-2 by nanomaterial-based point-of-care devices is another nanotechnology capability. Finally, nanotechnology can play an effective role as an agents carrier, such as agents for blocking angiotensin-converting enzyme 2 (ACE2) receptors, gene editing agents, and therapeutic agents. As a general conclusion, it can be said that nanoparticles can be widely used in disinfection applications outside in vivo. However, in in vivo applications, although it has provided promising results, it still needs to be evaluated for possible unintended immunotoxicity. Reviews like these can be important documents for future unwanted pandemics.

Indexed as

diagnosisnanotechnologypreventionSARS-CoV-2treatment

Identifiers

PMID35269270
PMCPMC8912597
OpenAlexW4214778001

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.